



*cancers*



an Open Access Journal by MDPI

## Testicular Cancer

Guest Editor:

**Dr. Joost L. Boormans**

Erasmus MC, Rotterdam,  
Netherlands

Deadline for manuscript  
submissions:

**closed (30 November 2021)**

### Message from the Guest Editor

Testicular Cancer (TC) is the most commonly diagnosed malignant tumor in males between the ages of 16 and 40 years. The incidence of TC continues to rise, and the vast majority of TC patients are diagnosed with clinical stage I disease, either non-seminoma or seminoma testis. The aim of this Special Issue of *Cancers* is to address the following important clinical knowledge gaps regarding the diagnosis and management of clinical stage I TC: i) the impact of TC diagnosis on psychological and sexual wellbeing and fertility of patients; ii) the need for new and improved detection of prognostic markers to more accurately identify patients at the highest risk of relapse following orchiectomy; iii) controversies surrounding risk-adapted management of adjuvant treatment; and iv) the importance of long-term TC survivorship and monitoring of late side-effects. I sincerely hope this issue of *Cancers* will be read with great interest by clinicians, researchers, and patients.



[mdpi.com/si/46908](https://mdpi.com/si/46908)

**Special** Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI